Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04502394
Title	Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Recruitment	Unknown status
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Kartos Therapeutics, Inc.
Indications	relapsed/refractory diffuse large B-cell lymphoma chronic lymphocytic leukemia
Therapies	Acalabrutinib + KRT-232
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| ITA \| GBR \| FRA \| CZE \| CHE \| BEL \| AUS